OR WAIT 15 SECS
The lab, which is currently available to customers, can handle highly potent compounds.
CordenPharma announced on Oct. 19, 2020 that it has completed the construction of its highly potent API laboratory in its Boulder, CO facility.
The lab, which is currently available to customers, can handle highly potent compounds with an OEL as low as 1 ng/m3, according to a company press release.
“Our new laboratory in Colorado is part of a development capacity expansion to address the strong market demand. This additional capacity benefits customers by expediting the onboarding of new projects,” said Jason Bertola, director of CordenPharma’s Global Highly Potent & Oncology Platform, in the press release.